Diagnosis and management of glutaric aciduria type I - Revised recommendations

Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, Peter Burgard

Research output: Contribution to journalArticleOtherpeer-review

171 Citations (Scopus)

Abstract

Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria. Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality. The neuropathological correlate is striatal injury which results from encephalopathic crises precipitated by infectious diseases, immunizations and surgery during a finite period of brain development, or develops insidiously without clinically apparent crises. Glutaric aciduria type I is caused by inherited deficiency of glutaryl-CoA dehydrogenase which is involved in the catabolic pathways of L-lysine, L-hydroxylysine and L-tryptophan. This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines). Glutaric aciduria type I is included in the panel of diseases that are identified by expanded newborn screening in some countries. It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. However, initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. Secondary dystonia is often difficult to treat, and the efficacy of available drugs cannot be predicted precisely in individual patients. The major aim of this revision is to re-evaluate the previous diagnostic and therapeutic recommendations for patients with this disease and incorporate new research findings into the guideline.

Original languageEnglish
Pages (from-to)677-694
Number of pages18
JournalJournal of Inherited Metabolic Disease
Volume34
Issue number3
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Cite this

Kölker, S., Christensen, E., Leonard, J. V., Greenberg, C. R., Boneh, A., Burlina, A. B., ... Burgard, P. (2011). Diagnosis and management of glutaric aciduria type I - Revised recommendations. Journal of Inherited Metabolic Disease, 34(3), 677-694. https://doi.org/10.1007/s10545-011-9289-5
Kölker, Stefan ; Christensen, Ernst ; Leonard, James V. ; Greenberg, Cheryl R. ; Boneh, Avihu ; Burlina, Alberto B. ; Burlina, Alessandro P. ; Dixon, Marjorie ; Duran, Marinus ; García Cazorla, Angels ; Goodman, Stephen I. ; Koeller, David M. ; Kyllerman, Mårten ; Mühlhausen, Chris ; Müller, Edith ; Okun, Jürgen G. ; Wilcken, Bridget ; Hoffmann, Georg F. ; Burgard, Peter. / Diagnosis and management of glutaric aciduria type I - Revised recommendations. In: Journal of Inherited Metabolic Disease. 2011 ; Vol. 34, No. 3. pp. 677-694.
@article{c0814bcb8bfb4d59b4df44ee4fbcb2ca,
title = "Diagnosis and management of glutaric aciduria type I - Revised recommendations",
abstract = "Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria. Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality. The neuropathological correlate is striatal injury which results from encephalopathic crises precipitated by infectious diseases, immunizations and surgery during a finite period of brain development, or develops insidiously without clinically apparent crises. Glutaric aciduria type I is caused by inherited deficiency of glutaryl-CoA dehydrogenase which is involved in the catabolic pathways of L-lysine, L-hydroxylysine and L-tryptophan. This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines). Glutaric aciduria type I is included in the panel of diseases that are identified by expanded newborn screening in some countries. It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. However, initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. Secondary dystonia is often difficult to treat, and the efficacy of available drugs cannot be predicted precisely in individual patients. The major aim of this revision is to re-evaluate the previous diagnostic and therapeutic recommendations for patients with this disease and incorporate new research findings into the guideline.",
author = "Stefan K{\"o}lker and Ernst Christensen and Leonard, {James V.} and Greenberg, {Cheryl R.} and Avihu Boneh and Burlina, {Alberto B.} and Burlina, {Alessandro P.} and Marjorie Dixon and Marinus Duran and {Garc{\'i}a Cazorla}, Angels and Goodman, {Stephen I.} and Koeller, {David M.} and M{\aa}rten Kyllerman and Chris M{\"u}hlhausen and Edith M{\"u}ller and Okun, {J{\"u}rgen G.} and Bridget Wilcken and Hoffmann, {Georg F.} and Peter Burgard",
year = "2011",
month = "6",
doi = "10.1007/s10545-011-9289-5",
language = "English",
volume = "34",
pages = "677--694",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer-Verlag London Ltd.",
number = "3",

}

Kölker, S, Christensen, E, Leonard, JV, Greenberg, CR, Boneh, A, Burlina, AB, Burlina, AP, Dixon, M, Duran, M, García Cazorla, A, Goodman, SI, Koeller, DM, Kyllerman, M, Mühlhausen, C, Müller, E, Okun, JG, Wilcken, B, Hoffmann, GF & Burgard, P 2011, 'Diagnosis and management of glutaric aciduria type I - Revised recommendations', Journal of Inherited Metabolic Disease, vol. 34, no. 3, pp. 677-694. https://doi.org/10.1007/s10545-011-9289-5

Diagnosis and management of glutaric aciduria type I - Revised recommendations. / Kölker, Stefan; Christensen, Ernst; Leonard, James V.; Greenberg, Cheryl R.; Boneh, Avihu; Burlina, Alberto B.; Burlina, Alessandro P.; Dixon, Marjorie; Duran, Marinus; García Cazorla, Angels; Goodman, Stephen I.; Koeller, David M.; Kyllerman, Mårten; Mühlhausen, Chris; Müller, Edith; Okun, Jürgen G.; Wilcken, Bridget; Hoffmann, Georg F.; Burgard, Peter.

In: Journal of Inherited Metabolic Disease, Vol. 34, No. 3, 06.2011, p. 677-694.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Diagnosis and management of glutaric aciduria type I - Revised recommendations

AU - Kölker, Stefan

AU - Christensen, Ernst

AU - Leonard, James V.

AU - Greenberg, Cheryl R.

AU - Boneh, Avihu

AU - Burlina, Alberto B.

AU - Burlina, Alessandro P.

AU - Dixon, Marjorie

AU - Duran, Marinus

AU - García Cazorla, Angels

AU - Goodman, Stephen I.

AU - Koeller, David M.

AU - Kyllerman, Mårten

AU - Mühlhausen, Chris

AU - Müller, Edith

AU - Okun, Jürgen G.

AU - Wilcken, Bridget

AU - Hoffmann, Georg F.

AU - Burgard, Peter

PY - 2011/6

Y1 - 2011/6

N2 - Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria. Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality. The neuropathological correlate is striatal injury which results from encephalopathic crises precipitated by infectious diseases, immunizations and surgery during a finite period of brain development, or develops insidiously without clinically apparent crises. Glutaric aciduria type I is caused by inherited deficiency of glutaryl-CoA dehydrogenase which is involved in the catabolic pathways of L-lysine, L-hydroxylysine and L-tryptophan. This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines). Glutaric aciduria type I is included in the panel of diseases that are identified by expanded newborn screening in some countries. It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. However, initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. Secondary dystonia is often difficult to treat, and the efficacy of available drugs cannot be predicted precisely in individual patients. The major aim of this revision is to re-evaluate the previous diagnostic and therapeutic recommendations for patients with this disease and incorporate new research findings into the guideline.

AB - Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria. Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality. The neuropathological correlate is striatal injury which results from encephalopathic crises precipitated by infectious diseases, immunizations and surgery during a finite period of brain development, or develops insidiously without clinically apparent crises. Glutaric aciduria type I is caused by inherited deficiency of glutaryl-CoA dehydrogenase which is involved in the catabolic pathways of L-lysine, L-hydroxylysine and L-tryptophan. This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines). Glutaric aciduria type I is included in the panel of diseases that are identified by expanded newborn screening in some countries. It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. However, initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. Secondary dystonia is often difficult to treat, and the efficacy of available drugs cannot be predicted precisely in individual patients. The major aim of this revision is to re-evaluate the previous diagnostic and therapeutic recommendations for patients with this disease and incorporate new research findings into the guideline.

UR - http://www.scopus.com/inward/record.url?scp=79959781632&partnerID=8YFLogxK

U2 - 10.1007/s10545-011-9289-5

DO - 10.1007/s10545-011-9289-5

M3 - Article

VL - 34

SP - 677

EP - 694

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 3

ER -